Bio News
Incyte expects Opzelura to surpass $1 billion in annual sales following its agreement with the Centers for Medicare & Medicaid Services (CMS). Second-quarter sales were $450 million due to a one-time reimbursement effect, while underlying sales grew 24% to $204 million. CEO Bill Mulligan warned of uncertainty in the pricing and reimbursement environment, but European approval and a hidradenitis suppurativa trial are expected to provide additional momentum.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
